24 July 2018 sales grew strongly by ~21% YoY (-2% QoQ) to INR7.4b (est. of INR7b), primarily due to a low base (1QFY18). EBITDA came in at INR1.4b (est. of INR951m), with the margin at 19.1% (YoY EBITDA is not comparable, as sales decline and higher other and employee expenses had resulted in EBITDA loss in 1QFY18). of INR790m) includes one-time expense of INR83m. Adjusting for this, PAT stood at INR969m. secondary sales grew 7.4% YoY in 1QFY19, as against 9.1% growth in the Indian Pharmaceutical Market (IPM). According to AIOCD, FDC-related market grew 17% YoY. GLXOs key products Augmentin, Calpol, and Zinetac (up ~25% YoY) saw healthy growth in 1QFY19.